1Mungall MM, Gaw A. Statin therapy in the elderly[J]. Current Opinion in Lipidology,2004,15:453-457.
2Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER) : a randomised controlled trial [J]. Lancet, 2002,360:1623 - 1630.
3Antonio M, Gotto Jr. Safety and statin therapy: reconsidering the risks and benefits[J]. Arch Intern Med, 2003,163 : 657-659.
4Strandberg TE, Pyorala K, Rediker DE, et al. Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S) [ J ]. Lancet, 2004,364:771-777.
5Gaw A. The care gap: underuse of statin therapy in the elderly [ J ]. Int J Clin Pract, 2004,58 : 777-785.
6Avezum A, Makdisse M, Spencer F, et al. Impact of age on management and outcome of acute coronary syndrome: observations from the Global Registry of Acute Coronary Events (GRACE)[ J]. Am Heart J,2005,149:67-73.
7Tran CT, Laupacis A, Mamdani MM, et al. Effect of age on the use of evidence-based therapies for acute myocardial infarction[ J]. Am Heart J, 2004,148 : 834-841.
8Doser S, Marz W, Reinecke MF, et al. Recommendations for statin therapy in the elderly [ J ]. Internist (Berl), 2004,45 : 1053-1062.
9Lipka L,Sager P,Strony J, et al. Efficacy and safety of coadministration of ezetimibe and statins in elderly patients with primary hypercholesterolemia[ J]. Drugs Aging,2004,21 : 1025-1032.
10Deedwania PC. Effect of aggressive versus moderate lipid-lowering therapy on myocardial ischemia: the rationale, design, and baseline characteristics of the Study Assessing Goals in the Elderly (SAGE)[J]. Am Heart J,2004,148:1053-1059.
二级参考文献10
1[1]Jick H, Zornberg GL, Jick SS, et al. Statins and the risk of dementia.Lancet, 2000;356(9242): 1627～ 1631
2[2]Hofman A, Ott A, Breteler MMB, et al. Atheroselerosis, apolipoprotein E, and prevalence of dementia and Alzheimer' s disease in the Rotterdam study. Lancet, 1997;349(9046): 151～154
3[3]American College of Medical Genetics/American Society of Human Genetics Working Group on ApoE and Alzheimer disease. Statement on use of apolipoprotein E testing for Alzheimer disease. JAMA, 1995; 274(20):1627 ～ 1629
4[4]Hyman B, Striekland D, Rebeck W. Role of the low - density lipoprotein receptor - related protein in β - amyloid metabolism and Alzheimer disease.Arch Neurol, 2000; 57(5): 646 ～ 650
5[5]Snowdon DA, Greiner LH, Mortimer JA, et al. Brain infarction and the clinical expression of Alzheimer disease. The Nun study. JAMA, 1997;277(10): 813～ 817
6[6]Wolozin B, Kellman W, Ruosscau P, et al. Decreased prevalence of Alzheimer disease associated with 3 - hydroxy - 3 - methyglutaryl coenzyme A reductase inhibitors. Arch Neurol, 2000; 57(10):1439～ 1443
7[7]Birkenhager WH, Wang JG, Staessen JA. Dementia and statins (letter).Lancet, 2001; 357(9259): 880
8[8]Ebrahim S, Shlomo YB, Smith GD, et al. Dementia and statins (letter).Lancet, 2001; 357(9259):882
9[9]Lowe G, Rumley A, Packard C, et al.. Dementia and statins (letter).Lancet, 2001; 357(9259): 881
10[10]Kast RE. Dementia and statins (letter). Lancet, 2001;357(9259) :881
6Kelley DE,Williams KV,Price JC,et al.Plasma fatty acids,adiposity,and variance of skeletal muscle insulin resistance in type 2 diabetes mellitus[J].J Clin Endocrinol Metab,2001,86:5412-5419.
7Ivan Yuen Fan Wong,Zheng-Dan He,Yu Huang,et al.Antioxidative Activities of Phenylethanod Glycosides from Ligustrum purpurascens[J].Journal of Agricultural Food and Chemicals,2001,49:3113-3119.
8Masafumi Okawa,Junei Kinjo,Chong-Yen yang,et al.Antioxidants in Ligustrum purpurascens[J].Natural Medicines,2001,55(4):209-212.
9More DW,Hessler JR,Chisolm GM.Low Density Lipoprotein Cytoxity Induced by Free Radical Peroxidation of Lipid[J].Lipid Res.J.,1983,24:1070.
10Kit-Man Lau,Zhen-Dan He,Hui Dong,et al.Anti-oxidative,anti-inflammatory and hepato-protective effects of Ligustrum robustum[J].Journal of Ethnophaomacology,2002,83:63-71.
